Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized double-blind trial of SHR4640 in primary gout with hyperuricemia
CTR20191376Phase 3Completed
- Sponsor
- Hengrui Therapeutics
- Start
- Jul 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of ruzinurad in gout, hyperuricemia, sponsored by Hengrui Therapeutics. Started Jul 2019; status: completed.
02
Drugs
ruzinurad
03
Conditions
gouthyperuricemia
Beyond the preview
Go deeper on CTR20191376.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20191376.